Skip to main content
OpenTrials
Completed

NCT Number: NCT04706468

To Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

To evaluate the antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Virus Infection

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Xiangya Hospital Central South University

Hunan, China

About this study

This study is a multicenter, randomized, double-blind, dose-ranging study to evaluate the efficacy and safety of different doses of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.

Approximately 200 patients will be randomly assigned to 1 of 4 treatments groups in a ratio of 1:1:1:1 to receive study treatment orally: "40 mg TG-1000", "80 mg TG-1000", "40mg+40mg TG-1000" or "placebo".

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide written informed consent.
  • Age ≥ 18 (or legal adult age) to < 65 years at the time of signing the informed consent.
  • Must have a positive result of Rapid influenza diagnostic test (RIDT) or Polymerase chain reaction (PCR).
  • The time interval between the onset of symptoms and the randomization is 48 hours or less.
  • Must be able to comply with all study procedures and assessments, including completion of the patient diary.

Exclusion criteria

  • Patients with severe influenza virus infection requiring inpatient treatment.
  • Patients with high risk factors may develop into severe cases.
  • Investigator suspects or confirms that patients with bronchitis, pneumonia, pleural effusion or interstitial disease through chest imaging examination.
  • Acute respiratory infection, otitis media or sinusitis within 2 weeks prior to Screening.
  • Purulent sputum or purulent tonsillitis.
  • Positive nucleic acid test for COVID-19.
  • Suspects allergic to active ingredients or excipients.
  • Body weight < 40 kg.
  • Has received anti-influenza drug.
  • Has received any investigational agents or devices for any indication within 30 days prior to Screening.
  • Patients who, in the opinion of the Investigator, may not be qualified or suitable for the study.

Treatment and study plan

TG-1000

Drug

Capsules taken orally

Primary outcomes

  1. The antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.

    Time frame: Up to Day 9

    The time between the initiation of the study treatment and the first time when the influenza virus RNA cannot be detected.

Secondary outcomes

  1. Time to alleviation of all influenza symptoms.

    Time frame: Up to Day 9

    The time between the initiation of the study treatment and the alleviation of influenza symptoms.

  2. The percentage of patients have positive for virus RNA by real time polymerase chain reaction(RT-PCR).

    Time frame: Up to Day 9

    The percentage of patients positive for virus RNA by RT-PCR.

  3. The change from baseline in virus RNA by RT-PCR (unit: log₁₀ virus particles/mL).

    Time frame: Up to Day 9

    The change from baseline in the amount of virus RNA.

  4. Area Under the Concentration (AUC) of virus RNA by RT-PCR and AUC of virus titer.

    Time frame: Up to Day 9

    AUC of the viral load by RT-PCR and AUC of viral titer measured from baseline to Day 9±2 or early termination (Visit 5).

  5. The percentage of patients whose symptoms have been alleviated at each time point.

    Time frame: Up to Day 9

    The percentage of patients whose symptoms are alleviated at each time point.

  6. The percentage of patients reporting normal temperature at each time point.

    Time frame: Up to Day 9

    The percentage of patients whose axillary temperature drops to less than 37ºC after the initiation of the study treatment in the analysis population.

  7. Time to resolution of fever.

    Time frame: Up to Day 9

    The time between the initiation of the study treatment and the resolution of fever.

  8. Body temperature at each time point.

    Time frame: Up to Day 9

    Measured axillary temperature.

  9. Time to return to preinfluenza health status.

    Time frame: Up to Day 9

    Patients will be asked to record their pre-influenza health status between 0 (worst possible health) and 10 (normal health).

  10. The visual analog scale (VAS) score change from baseline of quality of life (QOL) questionnaire.

    Time frame: Up to Day 9

    The VAS score change from baseline of QOL questionnaire.The QOL questionnaire consists 2 sections: the descriptive system and the VAS. The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is divided into 5 levels. The VAS records the patient's self-rated health on a 20-cm vertical visual analogue with "the best health the patient can imagine" as 100 and "the worst health the patient can imagine" as 0.

  11. Incidence of influenza-related complications (hospitalization, death, sinusitis, bronchitis, otitis media, and radiologically confirmed pneumonia).

    Time frame: Up to Day 9

    The percentage of patients in the analysis population who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an AE after the initiation of the study treatment.

  12. The percentage of patients taking acetaminophen.

    Time frame: Up to Day 9

    The percentage of patients who took acetaminophen.

Sponsors and collaborators

Lead sponsor

TaiGen Biotechnology Co., Ltd.

Industry

Collaborators

  • R&G Pharma Studies Co.,Ltd.

Registry information

Official study title

A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jan 12, 2021
Registry last updated
Mar 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.